呼吸道合胞病毒住院儿童重症疾病的风险因素
该观察性队列研究纳入2022年7月1日至2023年6月30日加拿大2家三级儿童医院709例<18岁RSV相关急性呼吸道感染住院或ICU患儿,主要结局为需无创或有创通气或死亡的重症疾病。204例(28.8%)发生重症,重症者较非重症者更年轻(中位2.6月 vs 18.6月,P<.001)。<2岁患儿中,<3月龄(ARR 2.34)、3至<6月龄(ARR 2.79)和早产(ARR 1.40)与重症相关;≥2岁患儿中,肺疾病及家庭氧疗(ARR 2.47)和神经、神经肌肉及发育疾病(ARR 1.89)与重症相关。作者认为这些发现支持对所有年幼儿童(包括早产儿)采取预防策略,≥2岁特定高危儿童可能获益。
要点
- 709例RSV住院患儿中204例(28.8%)发生重症(需无创或有创通气或死亡),重症者中位年龄2.6月 vs 非重症18.6月(P<.001)。
- <2岁患儿中,<3月龄(ARR 2.34,95%CI 1.43-3.84)、3至<6月龄(ARR 2.79,95%CI 1.65-4.70)和早产(ARR 1.40,95%CI 1.03-1.89)与重症相关。
- ≥2岁患儿中,肺疾病及家庭氧疗(ARR 2.47,95%CI 1.30-4.68)和神经、神经肌肉及发育疾病(ARR 1.89,95%CI 1.03-3.49)与重症相关。
- 作者认为这些发现支持对所有年幼儿童(包括早产儿)采取预防策略,≥2岁特定高危儿童可能有潜在获益。
适用人群与场景
- 2022年7月1日至2023年6月30日在2家加拿大三级儿童医院住院或入住ICU的<18岁RSV相关急性呼吸道感染患儿,共709例。
- 452例(63.8%)<2岁,257例(36.2%)≥2岁;中位年龄13.1月(IQR 2.0-36.6月),男孩442例(62.3%)。
研究设计与关键结果
- 观察性队列研究,纳入2家加拿大三级儿童医院709例<18岁RSV相关急性呼吸道感染住院或ICU患儿,主要结局为需无创或有创通气或死亡的重症疾病。
- 204例(28.8%)发生重症;重症者中位年龄2.6月(IQR 1.3-16.0月)vs 非重症者18.6月(IQR 4.5-39.1月),P<.001。
- <2岁患儿中,与重症相关的因素:年龄<3月龄(ARR 2.34,95%CI 1.43-3.84)、年龄3至<6月龄(ARR 2.79,95%CI 1.65-4.70)、早产(ARR 1.40,95%CI 1.03-1.89)。
- ≥2岁患儿中,与重症相关的因素:肺疾病及家庭氧疗(ARR 2.47,95%CI 1.30-4.68)、神经、神经肌肉及发育疾病(ARR 1.89,95%CI 1.03-3.49)。
证据类型、等级与局限
- 证据类型:观察性队列研究;原文未给出证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些发现支持对所有年幼儿童(包括早产儿)采取预防策略,≥2岁特定高危儿童可能有潜在获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A resurgence of respiratory syncytial virus (RSV)-associated acute respiratory tract infection (ARI) was observed in 2022 and 2023 after the COVID-19 pandemic. Changes in the demographic characteristics, disease severity, and outcomes of patients were observed, which could impact the identification of risk groups for interventions aimed at reducing the severity of RSV disease.
OBJECTIVES: To identify factors associated with severe clinical outcomes among children hospitalized with RSV-associated ARIs in 2022 and 2023.
DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study, conducted at 2 large, Canadian, tertiary-level pediatric hospitals, comprised all 709 cases of RSV-associated ARI among children younger than 18 years who were admitted to the hospital or intensive care unit (ICU) from July 1, 2022, to June 30, 2023.
EXPOSURE: Diagnosis of RSV-associated ARI.
MAIN OUTCOMES AND MEASURES: The primary outcome of severe disease was defined as requiring noninvasive or invasive ventilation or death. Risk factors for severe disease and ICU admission (secondary outcome) were assessed using multivariable Poisson regression, and results were reported as adjusted risk ratios (ARRs) with 95% CIs, with age-stratified models (<2 years and ≥2 years).
RESULTS: A total of 709 cases (median age, 13.1 months [IQR, 2.0-36.6 months]; 442 boys [62.3%]) were admitted with RSV-associated ARI; 452 (63.8%) were younger than 2 years, and 257 (36.2%) were aged 2 years or older. Severe disease was documented for 204 cases (28.8%). Patients with severe disease were younger than those with nonsevere disease (median age, 2.6 months [IQR, 1.3-16.0 months] vs 18.6 months [IQR, 4.5-39.1 months]; P < .001). Pulmonary disease and use of home oxygen (ARR, 2.47 [95% CI, 1.30-4.68]) and neurologic, neuromuscular, and developmental conditions (ARR, 1.89 [95% CI, 1.03-3.49]) were associated with severe disease among children aged 2 years or older. Among children younger than 2 years, age younger than 3 months (ARR, 2.34 [95% CI, 1.43-3.84]), age 3 to less than 6 months (ARR, 2.79 [95% CI, 1.65-4.70]), and prematurity (ARR, 1.40 [95% CI, 1.03-1.89]) were associated with severe disease.
CONCLUSIONS AND RELEVANCE: In this cohort study of children hospitalized with RSV in 2022 and 2023, severe RSV disease was more likely among those aged 2 years or older with pulmonary and neurologic, neuromuscular, or developmental conditions. For children younger than 2 years, age younger than 6 months and prematurity were the main risk factors. These findings support prevention strategies for all younger children, including premature infants, with potential benefit for children aged 2 years or older in specific high-risk groups.
参考来源
- Kirolos N, Mtaweh H, Datta RR, et al. Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus. JAMA Netw Open. 2025. PMID: 40214990. doi:10.1001/jamanetworkopen.2025.4666
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。